Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
Schizophr Res ; 264: 502-510, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38290375

ABSTRACT

BACKGROUND: The Mindfulness Ambassador Program (MAP) is a group-based, facilitated mindfulness-based intervention (MBI). We sought to determine the effectiveness of MAP on reducing negative psychotic symptoms and enhancing mindfulness skills among persons experiencing early psychosis. METHODS: We conducted a pragmatic randomized controlled trial (RCT) at three early psychosis intervention (EPI) programs in Ontario, Canada. Participants (N = 59) were randomly assigned to receive MAP (n = 29) for 1-hour weekly sessions over 3 months, or to treatment as usual (TAU, n = 30). Assessments were conducted at baseline, 3 months, and 6 months using the Self-Evaluation of Negative Symptoms (SNS) and Kentucky Inventory of Mindfulness Skills (KIMS). Linear mixed methods were used to assess the joint effects of group and time. RESULTS: At 3 months, participants who received MAP (n = 17) demonstrated greater reductions on the SNS relative to TAU (n = 15), which were clinically and statistically significant (-4.1; 95%CI -7.5, -0.7; p = 0.019). At 6 months, the difference between MAP (n = 10) and TAU (n = 13) was no longer statistically significant (-1.2; 95%CI -5.2,2.7; p = 0.54). On the KIMS, no significant effects were found at 3 months (+0.3; 95%CI -2.0,2.5; p = 0.82) or 6 months (+0.4; 95%CI -2.2,2.9; p = 0.79). CONCLUSIONS: We conducted one of the first multi-site RCTs of a MBI for early psychosis. Our findings indicated that MAP was more effective in reducing negative symptoms compared to TAU in the short term. Earlier reductions in negative psychotic symptoms may help facilitate recovery in the long term.


Subject(s)
Mindfulness , Psychotic Disorders , Humans , Mindfulness/methods , Psychotic Disorders/therapy , Ontario
3.
Trials ; 21(1): 922, 2020 Nov 11.
Article in English | MEDLINE | ID: mdl-33176853

ABSTRACT

BACKGROUND: Epilepsy extends far beyond seizures; up to 80% of children with epilepsy (CWE) may have comorbid cognitive or mental health problems, and up to 50% of parents of CWE are at risk for major depression. Past research has also shown that family environment has a greater influence on children's and parents' health-related quality of life (HRQOL) and mental health than epilepsy-related factors. There is a pressing need for low-cost, innovative interventions to improve HRQOL and mental health for CWE and their parents. The aim of this randomized controlled trial (RCT) is to evaluate whether an interactive online mindfulness-based intervention program, Making Mindfulness Matter (M3), can be feasibly implemented and whether it positively affects CWE's and parents' HRQOL and mental health (specifically, stress, behavioral, depressive, and anxiety symptoms). METHODS: This parallel RCT was planned to recruit 100 child-parent dyads to be randomized 1:1 to the 8-week intervention or waitlist control and followed over 20 weeks. The intervention, M3, will be delivered online and separately to parents and children (ages 4-10 years) in groups of 4-8 by non-clinician staff of a local community epilepsy agency. The intervention incorporates mindful awareness, social-emotional learning skills, and positive psychology. It is modeled after the validated school-based MindUP program and adapted for provision online and to include a parent component. DISCUSSION: This RCT will determine whether this online mindfulness-based intervention is feasible and effective for CWE and their parents. The proposed intervention may be an ideal vector to significantly improve HRQOL and mental health for CWE and their parents given its low cost and implementation by community epilepsy agencies. TRIAL REGISTRATION: ClinicalTrials.gov NCT04020484 . Registered on July 16, 2019.


Subject(s)
Epilepsy , Mindfulness , Child , Child, Preschool , Epilepsy/diagnosis , Epilepsy/therapy , Humans , Mental Health , Parents , Quality of Life , Randomized Controlled Trials as Topic
4.
Handb Clin Neurol ; 174: 379-388, 2020.
Article in English | MEDLINE | ID: mdl-32977894

ABSTRACT

Quality of life (QOL) is recognized as a key outcome of chronic health conditions and is increasingly used and recommended for clinical care and clinical trials. Neurocognitive developmental disorders and disabilities (NDD) are characterized by impairments or comorbidities in multiple areas of function, and, unsurprisingly, youth with NDD and their families have poorer QOL relative to their peers. The impact of NDD goes beyond the characteristic symptoms of the illness, and youth with NDD face numerous comorbidities and psychosocial problems that may have a large impact on QOL. In this chapter, first, we discuss the varying approaches and methodological considerations associated with the measurement of QOL and the implications of using "generic," "disease-specific," and proxy-reported measures of QOL. Second, we review the literature evaluating the QOL of youth with various NDD relative to healthy controls and factors associated with outcomes. Last, we conclude with a review of the literature outlining the importance of family environment, the compromised QOL of parents of youth with NDD, and the needs of parents. Evaluation of QOL is an important and recommended component of comprehensive care and clinical trials.


Subject(s)
Quality of Life , Child , Chronic Disease , Comorbidity , Humans , Interpersonal Relations , Parents
5.
Br J Psychiatry ; 214(4): 218-224, 2019 04.
Article in English | MEDLINE | ID: mdl-30482255

ABSTRACT

BACKGROUND: Late-life depression (LLD) is a disabling disorder and antidepressants are ineffective in as many as 60% of cases. Converging evidence shows a strong correlation between LLD and subsequent risk of cardiovascular disease. There is a need for new, well-tolerated, non-pharmacological augmentation interventions that can treat depressive symptoms as well as improve heart rate variability (HRV), an important prognostic marker for development of subsequent cardiovascular disease. Meditation-based techniques are of interest based on positive findings in other samples.AimsWe aimed to assess the efficacy of Sahaj Samadhi meditation (SSM), an underevaluated, standardised and manualised meditation intervention, on HRV and depressive symptoms. METHOD: Eighty-three men and women aged 60-85 years, with mild to moderate depression and receiving treatment as usual (TAU) were randomised to either the SSM or TAU arm. Those allocated to SSM attended 4 consecutive days of group meditation training, using personalised mantras followed by 11 weekly reinforcement sessions. HRV and Hamilton Rating Scale for Depression (HRSD; 17-item) score were measured at baseline and 12 weeks. RESULTS: All time and frequency domain measures of HRV did not significantly change in either arm. However, there was significant improvement in the SSM arm, compared with TAU, on the HRSD (difference in mean, 2.66; 95% CI 0.26-5.05; P = 0.03). CONCLUSIONS: Compared with TAU, SSM is associated with improvements in depressive symptoms but does not significantly improve HRV in patients with LLD. These results need to be replicated in subsequent studies incorporating a group-based, active control arm.Declaration of interestR.I.N. is the Director of Research and Health Promotion for the Art of Living Foundation, Canada and supervised the staff providing Sahaj Samadhi meditation. S.R. has received research funding from Satellite Healthcare for a mindfulness meditation trial in patients on haemodialysis. The remaining authors report no financial or other relationship relevant to the subject of this article.


Subject(s)
Depression/therapy , Heart Rate , Meditation , Aged , Aged, 80 and over , Depression/physiopathology , Female , Humans , Male , Middle Aged , Ontario , Psychiatric Status Rating Scales , Quality of Life , Self Care
SELECTION OF CITATIONS
SEARCH DETAIL